MindRank AI

MindRank (www.mindrank.ai) is an AI-driven biotech company with focus on “Undruggable” targets. The company started operations in 2021 and now consists of 35 scientists with R&D center in China and UK. The company is led by academicians of the British Royal Society, former R&D scientists from top pharma companies and the global AI competition winners. The team has successful experience in drug R&D and have a large number top publications including Nature Biomedical Engineering, Nature Machine Intelligence, Patterns (Cell Press) etc. By leveraging its proprietary AI driven drug discovery platform, MindRank has delivered a small molecule Preclinical Candidate (allosteric inhibitor) to a listed biotechnology company in Sept 2021. In Jan 2022, MindRank begins IND-enabling studies of its proprietary AI-designed drug (Class B GPCR), 8 months after program initiation. Both of the small molecule drugs are expected to enter clinical phase in 2022.